Form 4 for IRD Opus Genetics, Inc.

Accepted 2025-03-26 00:00:00 ET · period of report 2025-03-24 · accession 0000905148-25-001006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-03-26	2025-03-24	IRD	Gallagher Cam	Dir	A - Grant	—	+784.3K	861.4K	+1,018%	—
D	2025-03-26	2025-03-24	IRD	Gallagher Cam	Dir	A - Grant	—	+784.3K	784.3K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-03-24	A	A	784,314	—	861,361	D	—	—	(F1) Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275.
2	Derivative	Warrants (right to buy)	2025-03-24	A	A	784,314	—	784,314	D	$1.15 · — to 2030-03-24	784,314 Common Stock	(F1) Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. (F2) These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.